化合物 PTC-209 HBr|T6178|TargetMol

價(jià)格	￥6960	￥517	￥849
包裝	100mg	2mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 PTC-209 HBr	英文名稱:PTC-209 hydrobromide
CAS:1217022-63-3	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
產(chǎn)品類別: 抑制劑
貨號(hào): T6178

Product Introduction

Bioactivity

Name	PTC-209 hydrobromide
Description	PTC-209 hydrobromide (PTC-209 HBr) is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).
Cell Research	To determine whether pretreatment with the inhibitor affects tumor cell growth, cells are plated with the inhibitor for 4 d in vitro and plated in limiting doses in vitro without adding further inhibitor. Trypan blue exclusion is used to count viable cells. The in vitro sphere-initiating cell frequency is calculated after inhibitor treatment by evaluating the number of wells containing spheres. For the experiments where LDAs are set up following recovery of PTC-209 treated cells, 6-well plates were seeded with 1E6 cells per well and incubated overnight. Cells are subsequently treated for 4 d in triplicate with either DMSO vehicle or PTC-209 (0.01, 0.1, 1 and 10 μM). Drug treatments are washed off and 4 mL fresh suspension medium added to all wells. To assess cell viability following the 4 d treatment window, cells are trypsinized and counted at 0, 24, 72 and 120 h after removal of the drug. Long-lasting effects of the drug treatment on sphere-forming ability are assessed by plating LDAs (50,000, 10,000, 1,000,100, 10 and 1 cell per well) using the cells obtained 120 h after the 4-d drug treatment.(Only for Reference)
Kinase Assay	Untranslated region-mediated luciferase reporter expression: HEK293 cells are transfected with a GEMS reporter vector that contains the luciferase open-reading frame flanked by and under post-transcriptional control of the BMI-1 5′ and 3′ UTRs. The resulting stable cells (F8) are treated with PTC-209 or vehicle control overnight, and then luciferase reporter activity is determined using Bright-Glo assays. The assays are run in triplicate for each point, and the percentage of inhibition was calculated against vehicle control.
In vitro	PTC-209在人類結(jié)直腸癌細(xì)胞HCT116和人類纖維肉瘤細(xì)胞HT1080中同時(shí)抑制UTR介導(dǎo)的報(bào)告基因表達(dá)和內(nèi)源性BMI-1表達(dá)。PTC-209通過(guò)BMI-1依賴的方式減緩結(jié)直腸腫瘤細(xì)胞生長(zhǎng)。此外，PTC-209還通過(guò)不可逆的生長(zhǎng)抑制作用損害結(jié)直腸癌起始細(xì)胞(CICs)。[1]
In vivo	PTC-209（60 mg/kg/天，皮下注射）有效抑制了腫瘤組織中BMI-1的產(chǎn)生，并在帶有初級(jí)人類結(jié)腸癌異種移植物、人類結(jié)腸癌細(xì)胞系LIM1215或HCT116異種移植物的小鼠中停止了已建立腫瘤的生長(zhǎng)。PTC-209還在體內(nèi)減少了功能性結(jié)直腸CICs的頻率。[1]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	Ethanol : <1 mg/mL H2O : <1 mg/mL DMSO : 93 mg/mL (161.4 mM)
Keywords	cells \| HEK293T \| tumor \| breast \| cancer-initiating \| Inhibitor \| PTC-209 Hydrobromide \| PTC209 \| inhibit \| colon \| CICs \| Autophagy \| PTC 209 Hydrobromide \| PTC 209 \| PTC209 Hydrobromide \| lung \| PTC-209 \| anti-myeloma \| PTC209 hydrobromide \| PTC 209 hydrobromide
Inhibitors Related	Oxyresveratrol \| Guanidine hydrochloride \| Naringin \| Taurine \| Gefitinib \| Xylitol \| Hydroxychloroquine \| Curcumin \| Stavudine \| Myricetin \| Paeonol \| Sodium 4-phenylbutyrate

關(guān)鍵字： PTC-209 HBr|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.265100萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊(cè)資本：566.265100萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 Cbz-B3A|T14886|TargetMol

￥958

化合物 Propargyl-PEG4-amine|T16616|TargetMol

￥1133

化合物 2-Chloro-1-(2-ethoxyethyl)-1H-benzo[d]imidazole|T67128|TargetMol

詢價(jià)